Cochrane · systematic review · CD004448
Phytomedicines (medicines derived from plants) for sickle cell disease
Oniyangi, O, Cohall, DH · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
22
current version
GRADE rated
16
No studies
6
Included studies
NR
No studies 6 · 27.3%Ungraded 0 · 0%Very low 8 · 36.4%Low 8 · 36.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSummary of findings ‐ Niprisan® versus placebo for SCD
Population: adults and children with SCD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency, severity or duration of painful crises: frequency of mild, moderate and severe pain episodes Summary of findings ‐ Niprisan® vs placebo | no estimate extracted | 70 participants | Low Downgraded: risk of bias, indirectness |
Frequency of severe complications of SCD Summary of findings ‐ Niprisan® vs placebo | no estimate extracted | 70 participants | Low Downgraded: risk of bias, indirectness |
Frequency of hospital admissions from severe complications of SCD Summary of findings ‐ Niprisan® vs placebo | no estimate extracted | 70 participants | Low Downgraded: risk of bias, indirectness |
Any adverse events including hepatic and renal toxicity Summary of findings ‐ Niprisan® vs placebo | no estimate extracted | 80 participants | Low Downgraded: risk of bias, indirectness |
Frequency of blood transfusion Summary of findings ‐ Niprisan® vs placebo | no estimate extracted | NR | No studies |
Level of anaemia: change in level of haemoglobin (g/dL) Summary of findings ‐ Niprisan® vs placebo | no estimate extracted | 52 participants | Low Downgraded: risk of bias, indirectness |
Quality of life measures: self‐reported health, absence from work or school Summary of findings ‐ Niprisan® vs placebo | no estimate extracted | 70 participants | Very low Downgraded: risk of bias, indirectness |
Summary of findings ‐ Ciklavit® versus placebo for SCD
Population: adults and children with SCD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency, severity or duration of painful crises Summary of findings ‐ Ciklavit® vs placebo | no estimate extracted | 1 study · 87 participants | Low Downgraded: risk of bias, indirectness |
Frequency of severe complications of SCD Summary of findings ‐ Ciklavit® vs placebo | no estimate extracted | NR | No studies |
Frequency of hospital admissions from severe complications of SCD Summary of findings ‐ Ciklavit® vs placebo | no estimate extracted | NR | No studies |
Any adverse events including hepatic and renal toxicity Summary of findings ‐ Ciklavit® vs placebo | no estimate extracted | 1 study · 87 participants | Low Downgraded: risk of bias, indirectness |
Frequency of blood transfusion Summary of findings ‐ Ciklavit® vs placebo | no estimate extracted | NR | No studies |
Level of anaemia: packed cell volume Summary of findings ‐ Ciklavit® vs placebo | no estimate extracted | 1 study · 87 participants | Low Downgraded: risk of bias, indirectness |
Quality of life measures Summary of findings ‐ Ciklavit® vs placebo | no estimate extracted | NR | No studies |
Summary of findings ‐ Pfaffia paniculata versus placebo for SCD
Population: children with SCD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency, severity or duration of painful crises Summary of findings ‐ Pfaffia paniculata vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, indirectness |
Frequency of severe complications of SCD Summary of findings ‐ Pfaffia paniculata vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, indirectness |
Frequency of hospital admissions from severe complications of SCD Summary of findings ‐ Pfaffia paniculata vs placebo | no estimate extracted | NR | No studies |
Any adverse events including hepatic and renal toxicity Summary of findings ‐ Pfaffia paniculata vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, indirectness |
Frequency of blood transfusion Summary of findings ‐ Pfaffia paniculata vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, indirectness |
Level of anaemia: packed cell volume Summary of findings ‐ Pfaffia paniculata vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, indirectness |
Quality of life measures Summary of findings ‐ Pfaffia paniculata vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, indirectness |
Number of sickle cells, peripheral erythroblasts and reticulocytes Summary of findings ‐ Pfaffia paniculata vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, indirectness |